“Precision medicine is a paradigm shift that will produce tremendous improvements in the outcomes of patients with cancer.” This informative and entertaining debate will delve into the virtues and vices of precision medicine and examine the question of whether it really is the ‘game-changer’ many believe it to be. What side are you on?
Ian F. Tannock, CM, MD, PhD, DSc
Emeritus Professor of Medicine and Medical Biophysics
Princess Margaret Cancer Centre and University of Toronto
Dr. Tannock is Emeritus Professor of Medicine and Medical Biophysics at Princess Margaret Cancer Centre and University of Toronto. He obtained his PhD from the Institute of Cancer Research, London University, England, and his MD at University of Pennsylvania, Philadelphia, USA.
His clinical expertise is in GU (Genito Urinary) and breast cancer. His research investigated methods related to cancer clinical trials, and he chaired trials for men with metastatic prostate cancer that led to licensing of drugs that are used worldwide for this disease. Dr. Tannock is an editor of the Basic Science of Oncology textbook, now in its 5th edition that is used by trainees in all branches of oncology.
Dr. Tannock was a member of the Board of Directors of the American Society of Clinical Oncology (ASCO) from 2001-2004, and chairs the ASCO working group that organizes international clinical trials workshops. He received the alumnus award from M.D. Anderson Hospital, Houston, USA (1989), the O. Harold Warwick Prize from the National Cancer Institute of Canada (2003), an honorary degree (DSc) from London University, UK (2009), and the ESMO award (2012)—the first non-European to receive this award. He has been a board member of the European Organisation for Research and Treatment of Cancer (EORTC). Dr. Tannock was appointed to the Order of Canada in December 2013.
Uri Tabori, MD
Staff Haematologist/Oncologist, Division of Haematology/Oncology
The Hospital for Sick Children
Dr. Uri Tabori is a Staff Oncologist with the Division of Haematology/Oncology and a Senior Scientist within the SickKids Research Institute, holds the Garron Family Chair in Childhood Cancer Research, and is a Principal Investigator within the Arthur and Sonia Labatt Brain Tumor research Centre at The Hospital for Sick Children. He is also a Professor in the Department of Medical Biophysics, Institute of Medical Science and Paediatrics, University of Toronto.
He received his MD at the Hebrew University in Jerusalem and completed his specialized training in pediatrics at the Sorasky Medical Centre in the Department of Haematology/Oncology at the Chaim Sheba Medical Centre and Paediatric Neuro-Oncology at The Hospital for Sick Children.
Dr. Tabori’s clinical practice focuses on the treatment of children with cancer, with a particular focus on brain tumours and cancer predisposition. Based on his clinical background and expertise, his research focuses on translational aspects of cancer originating from patients’ need, through basic discoveries and clinical trials to changes in how society is managing specific cancers. Specifically, Dr. Tabori focuses on the development of systems for early detection, intervention and therapeutics in individuals highly predisposed to developing brain tumours. He is also studying mechanisms underlying brain tumour immortality and recurrence in the context of predisposition to cancer.
Dr. Tabori has been the recipient of numerous awards, including the Canadian Cancer Society’s Bernard and Francine Dorval Prize in 2016 and the Early Researcher Award from the Ontario Ministry of Development in Innovation in 2014.